Ocean Biotech announced that Wang Xiangao, a shareholder holding more than 5% of the total shares, plans to reduce its holdings by no more than 570,000 shares through centralized bidding transactions from January 12 to April 11, 2026, that is, no more than 0.68% of the total number of shares in the company. As of the disclosure date, Wang Xiangao held 648,482 shares of the company, accounting for 0.77%. The reason for the reduction in holdings was due to its own capital requirements. The source of shares was shares before the company's initial public offering and shares obtained by transferring capital reserves to increase share capital through equity distribution. There is uncertainty about the implementation of this holdings reduction plan and will not lead to a change in the company's control.

Ocean Biotech announced that Wang Xiangao, a shareholder holding more than 5% of the total shares, plans to reduce its holdings by no more than 570,000 shares through centralized bidding transactions from January 12 to April 11, 2026, that is, no more than 0.68% of the total number of shares in the company. As of the disclosure date, Wang Xiangao held 648,482 shares of the company, accounting for 0.77%. The reason for the reduction in holdings was due to its own capital requirements. The source of shares was shares before the company's initial public offering and shares obtained by transferring capital reserves to increase share capital through equity distribution. There is uncertainty about the implementation of this holdings reduction plan and will not lead to a change in the company's control.